Loading...
•
Sep 30, 2021
Revance Q3 2021 Earnings Report
Reported third quarter financial results and provided a corporate update.
Key Takeaways
Revance Therapeutics reported strong revenue growth in Q3 2021, driven primarily by increased sales of the RHA® Collection of dermal fillers. The company is engaging with the FDA to address deficiencies related to the BLA for DaxibotulinumtoxinA for Injection and focusing on strategic priorities including growing dermal filler revenue and expanding customer relationships through OPUL™.
RHA® Collection of dermal fillers revenue reached $18.3 million.
Over 2,500 aesthetic accounts across products and services.
Revance plans to request a Type A meeting with the FDA for DaxibotulinumtoxinA for Injection approval.
Announced positive topline results from the ASPEN-OLS Phase 3 study of DaxibotulinumtoxinA for Injection for cervical dystonia treatment.
Forward Guidance
Revance withdrew its previously announced cash guidance and expects to provide an updated cash guidance and its GAAP and Non-GAAP operating expense guidance for 2022 following its Type A meeting with the FDA.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...